PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers
European Urology Focus · 2024
DOI: 10.1016/j.euf.2024.08.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Urology Focus, 2024. Verfasst von Elena Castro. Beteiligte Einrichtung: Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: ecastro.imas12@h12o.es. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Gefördert von: Fundacion Cientifica de la Asociacion Espanola Contra el Cancer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: ecastro.imas12@h12o.es.
Förderung
- Fundacion Cientifica de la Asociacion Espanola Contra el Cancer
Zitieren
APA
Castro, E. (2024). PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers. European Urology Focus. https://doi.org/10.1016/j.euf.2024.08.005
Vancouver
Castro E. PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers. European Urology Focus. 2024. doi:10.1016/j.euf.2024.08.005
BibTeX
@article{Castro2024,
author = {Castro, Elena},
title = {PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers},
journal = {European Urology Focus},
year = {2024},
doi = {10.1016/j.euf.2024.08.005}
}
EUVIMED